Thomas Shenk
Thomas E. Shenk is the James A. Elkins Jr. Professor in the Life Sciences in the department of Molecular Biology at Princeton University.[1] Although his publications have contributed to the fields of biochemistry, cell biology, genetics, genomics, microbiology and virology, his present research interest involves the cytomegalovirus. Aside from academic involvement, Dr. Shenk has sat on the board of directors of Merck & Co.[2] and the Fox Chase Cancer Center.[3]
Thomas E. Shenk | |
---|---|
Nationality | American |
Alma mater | University of Detroit Rutgers University |
Known for | Human cytomegalovirus |
Scientific career | |
Institutions | Princeton University |
Career
Shenk received a BS in biology from the University of Detroit, and earned a Ph.D. in Microbiology from Rutgers University.[4]
Shank received in 1982 the Eli Lilly and Company-Elanco Research Award from the American Society for Microbiology. He was elected to the National Academy of Sciences in 1996,[5] and the American Academy of Arts and Sciences in 2002.[6] He served as a Howard Hughes Medical Institute investigator from 1998 to 1999.[7]
In 2021, Shenk transferred to Emeritus status within the Princeton department of Molecular Biology.[8]
References
- "Thomas Shenk profile". Shenk Lab Website. Retrieved 5 January 2022.
- "Thomas E. Shenk To Retire From Merck's Board of Directors". Merck website. Retrieved 5 January 2022.
- "Fox Chase Cancer Center Annual Report (2014)" (PDF). Retrieved 5 January 2022.
- "Graduate School of Biomedical Sciences Alumni Association- Thomas Shenk". Rutgers Graduate School of Biomedical Sciences. Retrieved 5 January 2022.
- "Thomas E. Shenk (member profile)". National Academy of Sciences member directory. Retrieved 5 January 2022.
- "Thomas E. Shenk profile". American Academy of Arts and Sciences member directory. Retrieved 5 January 2022.
- "Thomas E. Shenk, PhD". HHMI. Retrieved 5 January 2022.
- "Two Faculty Members Transfer to Emeritus Status". Princeton University- Department of Molecular Biology. Retrieved 5 January 2022.